Breye Therapeutics announced the successful completion of its phase 1b clinical trial of an oral therapy, danegaptide, for early treatment of non-proliferative diabetic retinopathy (NPDR) and ...

Ahead of the Clinical Trials at the Summit (CTS) meeting in Las Vegas, Nevada, Victor Gonzalez, MD, shared an overview of his presentation. Dr. Gonzalez is a trial investigator in the REMAIN follow-up ...

Clinical-stage biotechnology company PYC Therapeutics recently held a type B meeting with the US Food and Drug Administration (FDA) to discuss requirements for a new drug application (NDA) for the ...

Robert Collier said, “success is the sum of small efforts, repeated day in and day out.” So, as we approach the busiest retina meeting season, remember each small effort and give these pearls a try.

The Dextenza insert provides an additional measure of safety should patients be nonadherent to instructions for postoperative drops. We have all seen patients at a postoperative appointment without ...

Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic ...

New research links diffuse-trickling patterns in fundus autofluorescence to increased ellipsoidal zone loss, highlighting potential biomarkers for rapid geographic atrophy progression. The results of ...

Christina Weng, MD, spoke with us about her presentation on the emerging technology of home OCT and its role in AMD. She gave this presentation at Clinical Trials at the Summit meeting being held in ...

More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The trial is expected to close randomization in early December 2024. This ...

Session ID: 2025-06-29:380d1fd056eaddc3fed7671f Player Element ID: vjs_video_902 ...

Alkeus Pharmaceuticals, Inc., announced additional data from its Phase 2 clinical SAGA study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). In this trial patients ...

The National Institutes of Health (NIH) has shared that scientists have used an artificial intelligence (AI) program to enhance a device designed to see tissues in the back of the eye. This ...